One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases. Herein, we report a case of a 74-year-old male CML patient with intracranial stenosis of the internal carotid artery developed during treatment with nilotinib successfully cured by the intracranial stent, Wingspan.
Introduction
Chronic myeloid leukemia (CML) is a neoplastic disease of uncontrolled expansion of hematopoietic stem cells triggered by translocation of chromosome 9 and 22, 1,2 which further leads to constitutive activation of the oncogenic protein, BCR-ABL. 3 According to European LeukemiaNet, tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib and dasatinib, which block constitutive tyrosine kinase activity of BCR-ABL, have been recommended as a frontline therapy in CML in the chronic phase. 4 The number of CML patients treated by nilotinib has recently been increasing, as superiority of nilotinib to imatinib in newly diagnosed CML was proved and efficacy and safety of nilotinib in imatinib-resistant or imatinibintolerant patients has been reported. [5] [6] [7] [8] With increased use of nilotinib, there is growing evidence that this drug accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases, 9-14 conditions that cannot be controlled by antiplatelet and anticoagulant therapy. 9, 10 A more aggressive treatment strategy may be required for this condition although one has not yet reported. Here, we report a 74-yearold male CML patient with symptomatic intracranial stenosis of the internal carotid artery (ICA) caused by nilotinib who was successfully treated by introducing an intracranial stent to the ICA stenotic lesion, further enabling the patient to continue bosutinib to control CML. This is an educative case for those who specialize in both cancer and cerebrovascular diseases as more and more TKIs will be used in the near future for controlling CML.
Case presentation
A 74-year-old male was diagnosed with CML seven years ago and was initially treated with imatinib. Nineteen percent of BCR-ABL-positive cells were detected by fluorescent in situ hybridization at three and a half years after starting imatinib, and switching from imatinib to nilotinib was performed. There was no sign of abnormality at the intracranial ICA at this time (Figure 1(a) ). The patient started to suffer from repeated TIAs such as transient hemiplegia two and a half years after starting nilotinib treatment. Magnetic resonance angiography (MRA) at this time showed narrowing of the left intracranial ICA and basilar artery ( Figure 1(b) ). Nilotinib was discontinued as the primary suspect for causing intracranial vessel narrowing. The therapeutic agent was then switched to bosutinib, which had to be discontinued because of impairment of hepatic function of unknown cause. Administration of dasatinib was also attempted as a means of continuing treatment, but had to be discontinued as the patient again suffered from repeated episodes of right transient hemiplegia. Even the best medical therapy including dual antiplatelet therapy (aspirin and clopidogrel) proved unable to control TIA and the patient was unable to sit upright because of hemodynamic impairment of the cerebral vascular circulation. This hemodynamic cerebral vascular impairment was confirmed on single photon emission computed tomography (SPECT) using N-isopropyl-p-[ (Figure 2(b) ), which revealed insufficient cerebral blood flow in the left ICA territory. Cerebral vascular revascularization was deemed necessary not only for TIA control, but also to allow continuation of CML treatment.
Endovascular treatment including intracranial stent placement was chosen to accomplish this task. Percutaneous transluminal angioplasty (PTA) was performed in the stenotic right ICA using angioplasty balloon catheters (Gateway TM 1.5 mm Â 9 mm and 2 mm Â 9 mm; Stryker, Fremont, CA, USA) followed by intracranial stent placement (Wingspan Õ 3 mm Â 15 mm; Stryker, Kalamazoo, MI, USA). Sufficient vessel dilation was confirmed at the end of the procedure (Figure 2(a) and (c) ). Successful cerebral vascular revascularization was also confirmed on SPECT and the patient experienced no further TIAs after treatment (Figure 2(d) ). The patient was discharged with no neurological deficits and bosutinib treatment was able to be resumed. Patency of the ICA was angiographically confirmed three months after treatment (Figure 2(e) ).
Discussion
Evidence is accumulating that BCR-ABL TKIs can trigger vascular adverse events (VAEs) in CML patients. 15, 16 Among these TKIs, nilotinib is reported to have the greatest association with major arterial events, at 2.8 per 100 patient-years for nilotinib, compared to 0.1 per 100 patient-years for imatinib. Likewise, the incidence of cerebrovascular event is reported as 0.3 per 100 patient-years for nilotinib, but less than 0.1 per 100 patient-years for imatinib. 16 Several different factors reportedly contribute to the development of VAEs in patients taking nilotinib. 15 First, nilotinib has direct proatherogenic and antiangiogenic effects on vascular endothelial cells. Proatherogenic effects cause arterial stenosis that is reinforced by antiangiogenic effects, which block recanalization and reperfusion of the vessel once arterial stenosis occurs. 17 Other possible causes include vasospasm 11 and metabolic adverse effects, such as increased levels of cholesterol and fasting glucose, [18] [19] [20] although neither of these mechanisms was likely to be responsible for VAE for this patient, considering that no increase in cholesterol or fasting glucose level was observed. PTA and stent placement in stenotic regions of femoral or coronary arteries induced by nilotinib in CML patients have been reported previously. 9, 10, 15 On the other hand, no reports have described attempted revascularization of intracranial cerebral stenotic vessels caused by BCR-ABL TKIs. While the Wingspan stent is the only on-label device currently available for the treatment of symptomatic intracranial stenosis, use of this device should be considered with great caution, as randomized clinical trials have revealed that best medical treatment is safer and more effective than intracranial stenting for high-risk patients with intracranial artery stenosis. 21, 22 As a result, radical medical treatment including dual antiplatelet therapy should be first pursued for intracranial artery stenosis patients even if the condition is thought to be caused by BCR-ABL TKIs. However, intracranial PTA and/or stenting may benefit patients with cerebral vascular hemodynamic impairment even under aggressive medical treatment. 23 The present case underlines the importance of not excluding endovascular intervention options for medically uncontrollable intracranial vessel stenosis caused by BCR-ABL TKIs. The present patient, who was unable to sit upright because of cerebral vascular hemodynamic impairment even under sufficient medical treatment, not only achieved relief from TIAs after intracranial stenting but also was able to continue CML treatment using TKIs, which could have become impossible if the ischemic condition had been left untreated. In conclusion, intracranial stenting may offer an effective treatment option for intracranial stenosis lesions caused by BCR-ABL TKIs.
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